194 related articles for article (PubMed ID: 37974430)
1. The impact of second transurethral resection on survival outcomes in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin therapy.
Kikuchi H; Abe T; Miyake M; Miyata H; Matsumoto R; Osawa T; Nishimura N; Fujimoto K; Inokuchi J; Yoneyama T; Tomida R; Numakura K; Matsushita Y; Matsumoto K; Sato T; Taoka R; Kobayashi T; Kojima T; Matsui Y; Nishiyama N; Kitamura H; Nishiyama H; Shinohara N
Jpn J Clin Oncol; 2024 Feb; 54(2):192-200. PubMed ID: 37974430
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of bacillus Calmette-Guérin therapy without a maintenance schedule for high-risk non-muscle-invasive bladder cancer in the second transurethral resection era.
Kikuchi H; Abe T; Matsumoto R; Osawa T; Maruyama S; Murai S; Shinohara N
Int J Urol; 2022 Mar; 29(3):251-258. PubMed ID: 34894009
[TBL] [Abstract][Full Text] [Related]
3. Insignificant role of bacillus Calmette-Guérin maintenance therapy after complete transurethral resection of bladder tumor for intermediate- and high-risk non-muscle-invasive bladder cancer: Results from a randomized trial.
Nakai Y; Anai S; Tanaka N; Chihara Y; Haramoto M; Otani T; Nakagawa Y; Hirao Y; Konishi N; Fujimoto K
Int J Urol; 2016 Oct; 23(10):854-860. PubMed ID: 27416975
[TBL] [Abstract][Full Text] [Related]
4. Single immediate instillation of chemotherapy is associated with decreased recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer who receive adjuvant induction bacillus Calmette-Guérin therapy.
Fujita N; Hatakeyama S; Momota M; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
Int J Urol; 2022 Aug; 29(8):867-875. PubMed ID: 35577361
[TBL] [Abstract][Full Text] [Related]
5. The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guérin.
Sfakianos JP; Kim PH; Hakimi AA; Herr HW
J Urol; 2014 Feb; 191(2):341-5. PubMed ID: 23973518
[TBL] [Abstract][Full Text] [Related]
6. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
[TBL] [Abstract][Full Text] [Related]
7. Significance of the interval between first and second transurethral resection on recurrence and progression rates in patients with high-risk non-muscle-invasive bladder cancer treated with maintenance intravesical Bacillus Calmette-Guérin.
Baltacı S; Bozlu M; Yıldırım A; Gökçe Mİ; Tinay İ; Aslan G; Can C; Türkeri L; Kuyumcuoğlu U; Mungan A
BJU Int; 2015 Nov; 116(5):721-6. PubMed ID: 25715815
[TBL] [Abstract][Full Text] [Related]
8. Patients with Non-Muscle-Invasive Bladder Cancer Previously Treated with Nephroureterectomy Have a High Risk of Recurrence after Bacillus Calmette-Guérin Intravesical Instillation Therapy.
Maeyama R; Ikeda M; Shimura S; Amano N; Murakami Y; Yamada Y; Koguchi D; Tachibana T; Kawamura M; Sakata Y; Hagiwara M; Matsumoto K; Iwamura M
Chemotherapy; 2023; 68(4):190-196. PubMed ID: 35390791
[TBL] [Abstract][Full Text] [Related]
9. Increased risk of bladder cancer recurrence due to bacillus Calmette-Guérin shortage in Brazil.
Murta CB; Hayek KKRE; Dias BC; Yorioka MAW; Cassao VD; Claro JFA
Rev Assoc Med Bras (1992); 2024; 70(5):e20231116. PubMed ID: 38775530
[TBL] [Abstract][Full Text] [Related]
10. The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial.
Gontero P; Oderda M; Mehnert A; Gurioli A; Marson F; Lucca I; Rink M; Schmid M; Kluth LA; Pappagallo G; Sogni F; Sanguedolce F; Schiavina R; Martorana G; Shariat SF; Chun F
J Urol; 2013 Sep; 190(3):857-62. PubMed ID: 23545101
[TBL] [Abstract][Full Text] [Related]
11. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
Shepherd AR; Shepherd E; Brook NR
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study.
Järvinen R; Marttila T; Kaasinen E; Rintala E; Aaltomaa S; Kallio J; Liukkonen T; Puolakka VM; Seppänen M; Tuhkanen K; Vaarala M; Viitanen J; Boström PJ;
Eur Urol; 2015 Oct; 68(4):611-7. PubMed ID: 25748117
[TBL] [Abstract][Full Text] [Related]
13. External validation of European Organization for Research and Treatment of Cancer and Spanish Urological Club for Oncological Treatment scoring models to predict recurrence and progression in Japanese patients with non-muscle invasive bladder cancer treated with bacillus Calmette-Guérin.
Kohjimoto Y; Kusumoto H; Nishizawa S; Kikkawa K; Kodama Y; Ko M; Matsumura N; Hara I
Int J Urol; 2014 Dec; 21(12):1201-7. PubMed ID: 25074295
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes after intravesical bacillus Calmette-Guérin for the highest-risk non-muscle-invasive bladder cancer newly defined in the Japanese Urological Association Guidelines 2019.
Miyamoto T; Miyake M; Toyoshima Y; Fujii T; Shimada K; Nishimura N; Iida K; Nakahama T; Hori S; Gotoh D; Nakai Y; Torimoto K; Tanaka N; Ohbayashi C; Fujimoto K
Int J Urol; 2021 Jul; 28(7):720-726. PubMed ID: 33734503
[TBL] [Abstract][Full Text] [Related]
15. Should intravesical Bacillus Calmette-Guerin (BCG) treatment be administered to patients with T0 after repeat transurethral resection of bladder tumor in patients with high-risk non-muscle invasive bladder cancer?
Yuk HD; Jeong CW; Kwak C; Kim HH; Ku JH
PLoS One; 2018; 13(11):e0208267. PubMed ID: 30496283
[TBL] [Abstract][Full Text] [Related]
16. Impact of chronic kidney disease on oncological outcomes in patients with high-risk non-muscle-invasive bladder cancer who underwent adjuvant bacillus Calmette-Guérin therapy.
Fujita N; Hatakeyama S; Okita K; Momota M; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
Urol Oncol; 2021 Mar; 39(3):191.e9-191.e16. PubMed ID: 32713622
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
Grabe-Heyne K; Henne C; Odeyemi I; Pöhlmann J; Ahmed W; Pollock RF
J Med Econ; 2023; 26(1):411-421. PubMed ID: 36897006
[TBL] [Abstract][Full Text] [Related]
18. Impact of age >70 years on oncological outcomes in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guérin.
Contieri R; Grajales V; Tan WS; Martini A; Sood A; Hensley P; Bree K; Lobo N; Nogueras-Gonzalez GM; Guo CC; Navai N; Dinney CP; Kamat AM
BJU Int; 2024 Jan; 133(1):63-70. PubMed ID: 37442564
[TBL] [Abstract][Full Text] [Related]
19. [A Randomized Controlled Study of Intravesical Instillation Therapy of Bacillus Calmette-Guérin vs. Epirubicinin Treating Non-muscular Invasive Bladder Cancer].
Yang WX; Shao YX; Hu X; Xiong SC; Liu Y; Li X
Sichuan Da Xue Xue Bao Yi Xue Ban; 2021 Mar; 52(2):326-333. PubMed ID: 33829710
[TBL] [Abstract][Full Text] [Related]
20. Intravesical Bacillus Calmette-Guerin in Ta and T1 Bladder Cancer.
Shelley MD; Court JB; Kynaston H; Wilt TJ; Fish RG; Mason M
Cochrane Database Syst Rev; 2000; 2000(4):CD001986. PubMed ID: 11034738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
